Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05192369 · ClinicalTrials.gov registry record · Phase 1
A Randomized Study to Evaluate the Effects of CTP-543 on the QT/QTc Intervals in Health Volunteers
A Phase 1 study, sponsored by Concert Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT05192369 is a Phase 1 study that has completed, run by Concert Pharmaceuticals. The registered enrollment target is 48 participants.
The verdict
NCT05192369, a Phase 1 study, has completed, sponsored by Concert Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
This is a four-arm, randomized, crossover, placebo and active controlled study to evaluate of the effect of therapeutic and supratherapeutic doses of CTP-543 on the QT/QTc intervals in healthy volunteers
Interventions
- DRUG Placebo
- DRUG Moxifloxacin
- DRUG CTP-543
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2022-01-04 |
| Est. Completion | 2022-01-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05192369
The ClinicalTrials.gov registry entry for NCT05192369 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Concert Pharmaceuticals, which has 24 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT05192369 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05192369 about?
NCT05192369 is a clinical study titled "A Randomized Study to Evaluate the Effects of CTP-543 on the QT/QTc Intervals in Health Volunteers". This is a four-arm, randomized, crossover, placebo and active controlled study to evaluate of the effect of therapeutic and supratherapeutic doses of CTP-543 on the QT/QTc intervals in healthy volunteers
What is the current status of trial NCT05192369?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2022-01-04. Estimated completion is 2022-01-28.
What interventions are being tested in trial NCT05192369?
The interventions under investigation include: Placebo (DRUG), Moxifloxacin (DRUG), CTP-543 (DRUG).
Who is sponsoring clinical trial NCT05192369?
This trial is sponsored by Concert Pharmaceuticals, which has 24 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.